TLX vs LEGN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TLX · Telix Pharmaceuticals$8.37 ▼ 3.90%
LEGN · Legend Biotech$15.25 ▼ 5.28%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- TLX -8.7%
- LEGN -43.8%
Head to head
| Metric | TLX | LEGN |
|---|---|---|
| Price | $8.37 | $15.25 |
| Change today | ▼ 3.90% | ▼ 5.28% |
| Market cap | $2.84B | $2.96B |
| Return, 3 months | -28.3% | -27.2% |
| Return, year to date | +11.7% | -29.9% |
| Return, 1 year | -6.1% | -45.9% |
| P/E (TTM) | 86.3 | – |
| P/B | 6.8 | 2.3 |
| P/E percentile vs own 5y | 40th | 0th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +55.6% | +32.0% |
| Net profit growth (YoY) | -121.2% | +230.6% |
| Gross margin | 53.7% | 57.0% |
| Operating margin | 5.3% | 2.6% |
| Net margin | 3.8% | 0.0% |
| Return on equity | 7.4% | 0.0% |
| Analyst target vs. price | +138.9% | +174.8% |
| Analyst buy share | 100% | 60% |
| RSI (14) | 34 | 31 |
| 30-day volatility | 55.0% | 82.6% |
| Max drawdown, 1 year | -37.3% | -58.0% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LEGN is the largest of the group by market value.
- TLX has returned the most over the past year.
- TLX is growing revenue fastest.
- TLX keeps the most profit per dollar of sales.
- TLX has been the calmest stock over the last 30 days.